SKU: OPC-ABIRAPRO-250-120
Abirapro 250mg Tablet contains Abiraterone Acetate 250 mg and is a prescription medicine used as part of hormone-based treatment for certain types of advanced prostate cancer.
Abirapro 250mg Tablet contains Abiraterone Acetate 250 mg and is a prescription anti-cancer medicine used as part of hormone-based treatment for certain types of advanced prostate cancer. It works by reducing the production of androgens, including testosterone, which can help slow the growth and progression of prostate cancer cells that depend on these hormones.
Abirapro is generally used under the supervision of an oncologist or other qualified healthcare professional. The treatment plan may include other medicines, and the exact dose, treatment duration and combination of medicines depend on the patient's diagnosis, medical history and response to treatment.
For more pharmaceutical products and healthcare-related products, explore our healthcare product collection.
Abirapro 250mg Tablet is an oral medicine containing Abiraterone Acetate 250 mg. It belongs to a group of medicines used in hormone-based treatment of prostate cancer. Abiraterone works by reducing the body's production of androgens, hormones that can support the growth of certain prostate cancer cells.
Because Abirapro is a prescription oncology medicine, it should only be used when prescribed by a qualified healthcare professional. The medicine should not be started, stopped or adjusted without medical advice.
For additional information about abiraterone and its approved uses, patients and healthcare professionals can also consult the MedlinePlus medicine information.
Abirapro 250mg Tablet is used as part of treatment for certain forms of advanced prostate cancer. The medicine may be prescribed when prostate cancer has spread or when cancer continues to grow despite treatments intended to lower androgen levels.
Abiraterone Acetate is used in specific treatment settings for advanced prostate cancer. The exact treatment approach depends on the stage and characteristics of the cancer and the patient's overall health.
Abirapro works by lowering androgen production. This is important because some prostate cancer cells use male hormones such as testosterone to grow and survive.
Abiraterone therapy may be used together with other prescribed medicines as part of an overall prostate cancer treatment plan. Your oncologist will determine which medicines should be used together and for how long.
Abirapro contains Abiraterone Acetate, which helps reduce the production of androgens in the body. Lower androgen levels can be useful in the treatment of prostate cancers that depend on these hormones.
When prescribed for an appropriate cancer diagnosis, Abirapro can form part of a hormone-based treatment strategy intended to slow cancer progression.
Unlike medicines that directly destroy cancer cells, abiraterone works by interfering with hormone production. This helps reduce the hormonal stimulation that may contribute to the growth of certain prostate cancer cells.
Abirapro is supplied as an oral tablet, allowing it to be incorporated into a prescribed treatment schedule at home under appropriate medical supervision.
Abiraterone is used in specific advanced prostate cancer treatment settings. The decision to use this medicine is made by the treating oncologist after considering the patient's cancer type, stage, previous treatment and overall health.
Abirapro contains Abiraterone Acetate, which inhibits an enzyme called CYP17. This enzyme is involved in the production of androgens. By inhibiting this pathway, abiraterone reduces androgen production in the body.
Some prostate cancer cells rely on androgen hormones to grow. By lowering the availability of these hormones, Abirapro can help slow the hormonal stimulation of cancer cells as part of a prescribed treatment plan.
Take Abirapro exactly as prescribed by your oncologist or healthcare professional. The tablet should be swallowed whole with water. Do not crush, chew or break the tablet unless your doctor specifically instructs you to do so.
Abirapro is generally taken on an empty stomach. Taking abiraterone with food can significantly increase the amount of medicine absorbed into the body and may increase the risk of adverse effects. Follow the timing instructions provided by your doctor and the current product information carefully.
Do not change the prescribed schedule, stop treatment or take additional tablets without discussing it with your healthcare professional.
The dosage of Abirapro is determined by the treating doctor according to the patient's cancer diagnosis, treatment plan and individual medical circumstances. The strength of the tablet does not by itself determine how many tablets a particular patient should take.
Abiraterone is commonly prescribed as part of a combination treatment plan, and the accompanying medicines and monitoring requirements are important parts of therapy. Therefore, patients should follow the exact prescription provided by their oncologist rather than using a dose recommended for another person.
Never increase, reduce or repeat the dose without medical advice. If you have questions about your prescribed schedule, speak with your oncology team or pharmacist.
Abiraterone treatment can cause side effects, although not everyone experiences them. Possible adverse effects may include tiredness, joint swelling or discomfort, nausea, headache, hot flashes, diarrhoea, indigestion, increased blood glucose and changes in blood pressure or other laboratory values.
Because Abiraterone can affect hormone production and certain body functions, your doctor may recommend regular blood tests and other monitoring during treatment.
Contact your healthcare professional if you develop unusual swelling, severe weakness, persistent vomiting, significant changes in blood pressure, yellowing of the skin or eyes, dark urine or other concerning symptoms.
Abiraterone can affect liver function in some patients. Your doctor may perform blood tests to monitor liver enzymes before and during treatment.
Tell your doctor if you have a history of liver disease or abnormal liver function tests. Do not ignore symptoms such as yellowing of the skin or eyes, dark urine or unusual abdominal discomfort.
Abiraterone treatment can affect mineralocorticoid levels and may contribute to increased blood pressure, fluid retention or changes in potassium levels in some patients.
Your healthcare professional may monitor blood pressure, potassium and fluid retention during treatment. Inform your doctor if you notice unusual swelling, shortness of breath or significant changes in blood pressure.
Tell your doctor about all prescription medicines, non-prescription medicines, vitamins and herbal supplements you currently take. Some medicines can affect abiraterone metabolism or increase the likelihood of unwanted effects.
Do not start a new medicine or supplement without discussing it with your doctor or pharmacist during Abirapro treatment.
Abiraterone is not intended for use in women. Women who are pregnant or may become pregnant should avoid handling damaged or crushed tablets unless appropriate protective precautions are followed.
Effective contraception may be required during treatment because abiraterone can potentially pose risks to an unborn baby. Follow the contraception advice provided by the treating healthcare professional.
Abirapro is not intended for use in women, and breastfeeding considerations should be discussed with a healthcare professional. If there is any possibility of exposure to the medicine, seek medical advice regarding appropriate precautions.
If you miss a scheduled dose of Abirapro, follow the instructions provided by your oncologist or pharmacist. Do not take an extra dose unless your healthcare professional specifically tells you to do so.
If you miss multiple doses or are unsure about what to do, contact your treating healthcare professional for guidance.
Abirapro should only be taken by patients for whom it has been prescribed as part of an appropriate prostate cancer treatment plan. The decision to prescribe abiraterone depends on the patient's cancer diagnosis, stage, previous treatments and overall medical condition.
This medicine should not be used as a general health supplement or taken without a confirmed medical indication.
Store Abirapro according to the instructions provided on the original product packaging. Current product information recommends storing the medicine below 30°C.
Keep the tablets in their original packaging, away from excessive heat and moisture. Keep the medicine out of reach of children and do not use tablets from damaged or tampered packaging.
Abirapro 250mg Tablet is a prescription medicine containing Abiraterone Acetate 250 mg. It is used as part of hormone-based treatment for certain types of advanced prostate cancer.
Abirapro is used in specific treatment settings for advanced prostate cancer. Your oncologist determines whether it is appropriate based on your cancer diagnosis and treatment plan.
The active ingredient is Abiraterone Acetate 250 mg.
Abiraterone inhibits CYP17, an enzyme involved in androgen production. By reducing androgen production, it can help limit hormonal stimulation of certain prostate cancer cells.
Abirapro may be prescribed with other medicines as part of a cancer treatment plan, but your doctor should review all medicines and supplements you take to identify potential interactions.
Store Abirapro according to the product label. Current product information recommends storage below 30°C and protection from inappropriate environmental conditions.
For more pharmaceutical and healthcare products, visit our healthcare product collection and explore other available products.
For reliable general medicine information, you can also refer to MedlinePlus drug information.
This product description is provided for general informational purposes only and does not replace medical advice, diagnosis or treatment. Abirapro 250mg Tablet is a prescription anti-cancer medicine and should be used only under the supervision of a qualified healthcare professional.
Dosage, treatment duration, combination medicines, monitoring and suitability vary from patient to patient. Always follow the prescription provided by your oncologist and check the original product packaging for the latest product information.
| Brand | Abirapro |
| Manufacturer | Glenmark Pharmaceuticals Ltd |
| Composition | Abiraterone Acetate 250 mg |
| Package | 1 × 120 Tablets |
| Ship time | 5-10 Business Days |
Free Shipping
For all oders over $99
Secure Payment
100% secure payment
24/7 Support
Online top support